Preliminary Study of Peel Force and Discomfort of Removal of Adhesive Barriers in Normal and Peristomal Skin

NCT ID: NCT02003404

Last Updated: 2016-11-11

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

17 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-11-30

Study Completion Date

2014-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This purpose of this study is to look at three commercially available ostomy barriers on peristomal (around the stoma) skin. Repeated barrier application and removal over years causes changes to the skin that the investigators wish to investigate. The primary objective is to measure peel force on normal skin and peel force on peristomal skin, with the intent of determining if differences occur. The study hypotheses is that no differences exist.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a single center, non-invasive exploratory study utilizing a sample of convenience. This study compares three commercially available barrier materials on peristomal skin and normal abdominal skin.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dermatologic Complications

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

ostomy appliance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control Abdominal Skin

Apply SoftFlex (standard wear commercial skin barrier), FlexWear (standard wear commercial skin barrier), and FlexTend (extended wear commercial skin barrier), material to non-peristomal abdominal skin.

Control Abdominal Skin

Intervention Type DEVICE

Three barrier materials will be peeled from abdominal skin after a set period at a set rate.

Peristomal Abdominal Skin

Apply SoftFlex, FlexWear and FlexTend barrier material to peristomal abdominal skin.

Peristomal Abdominal Skin

Intervention Type DEVICE

Three barrier materials will be peeled from abdominal skin after a set period at a set rate.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Control Abdominal Skin

Three barrier materials will be peeled from abdominal skin after a set period at a set rate.

Intervention Type DEVICE

Peristomal Abdominal Skin

Three barrier materials will be peeled from abdominal skin after a set period at a set rate.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

SoftFlex FlexWear FlexTend SoftFlex FlexWear FlexTend

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Colostomy, Ileostomy, or Urostomy patients at least 6 months post-surgery
* Males or females, age 18 to 80 years old at the time of enrollment
* Body Mass Index (BMI) between 18 and 50
* Willing to have two approximately 5" x 5" areas of the abdomen trimmed with a surgical clipper -- one in a ring around the stoma, and one on the opposite side
* Willing to remain within the testing room for the duration of the study
* Willing to allow a third person in the room as a witness for the duration of the study
* Able to position oneself onto and off of the examining table without the assistance of the Investigator
* Willing to refrain from vigorous exercise for the duration of the study
* Willing to not take any anti-inflammatory medications (except for Tylenol/acetaminophen) starting 48 hours prior to the study and for the duration of the study
* Willing to bring an extra barrier and replace their barrier worn during the study.
* Willing to follow the protocol as demonstrated by signing the Informed Consent Form
* In the opinion of the Investigator or qualified site personnel is qualified to participate

Exclusion Criteria

* Clinically significant diseases, which may or may not be confined to the testing site, that may contraindicate participation; including but not limited to psoriasis, eczema, atopic dermatitis, and active cancer
* Use of topical drugs on the application site within 1 month.
* Use of lotions, creams, powders or oils on the application site in the 24 hours prior to application
* Pregnancy, lactation or planning a pregnancy as determined by interview only
* Other medical conditions, for example uncontrolled diabetes, which in the Investigator's judgment, makes the subject ineligible or places the subject at undue risk
* Participation in any clinical test either using the abdomen as a test site or using systemic therapy within the previous thirty days
* Damaged skin or other skin conditions in or near test sites which includes sunburn, scars, numerous moles or other disfiguration of the test site
* Significant adipose tissue at the test site that would preclude adequate adhesion of the study devices
* Known allergy to any of the test materials
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Loyola University

OTHER

Sponsor Role collaborator

Hollister Incorporated

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

James Swan, MD

Role: PRINCIPAL_INVESTIGATOR

Loyola University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

La Grange Center for Health

La Grange Park, Illinois, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LUHSC IRB #: 205654091813

Identifier Type: OTHER

Identifier Source: secondary_id

5642-O

Identifier Type: -

Identifier Source: org_study_id